Press releases

(November 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the Interventional Procedures Advisory Committee (IPAC) of the National Institute for Clinical...

(October 28, 2004) -- Boston Scientific Corporation (NYSE:BSX) today announced that it has launched a full line of mid-urethral sling products for the treatment of female stress urinary...

(October 27, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the start of enrollment in the ARRIVE 2 registry program, which plans to enroll 5,000 patients at approximately 60...

(October 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its Board of Directors has authorized the repurchase of up to 50 million shares of the Company's common stock...

(October 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2004. Highlights: Net sales of $1.482 billion, an...

(October 13, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its new coronary...

(October 6, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2004 on Tuesday, October 19,...

and Washington, D.C. (October 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting safety from three post-market registries associated with its TAXUS™...

and Washington, D.C. (October 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its TAXUS V clinical trial. The trial is assessing the slow-release...

and Washington, D.C. (September 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its TAXUS IV clinical trial. The benefits reported at 12 months...